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Efficacy of live oral rotavirus vaccines by duration of 
follow-up: a meta-regression of randomised controlled trials
Andrew Clark*, Kevin van Zandvoort*, Stefan Flasche, Colin Sanderson, Julie Bines, Jacqueline Tate, Umesh Parashar, Mark Jit
Summary
Background The duration of protection offered by rotavirus vaccines varies across the world, and this variation is 
important to understanding and predicting the effects of the vaccines. There is now a large body of evidence on the 
efficacy of live oral rotavirus vaccines in different settings, but these data have never been synthesised to obtain robust 
estimates of efficacy by duration of follow-up. Our aim is to estimate the efficacy of live oral rotavirus vaccines at each 
point during follow-up and by mortality stratum.
Methods In our meta-regression study, we identified all randomised controlled trials of rotavirus vaccines published 
until April 4, 2018, using the results of a Cochrane systematic review, and cross checked these studies against those 
identified by another systematic review. We excluded trials that were based on special populations, trials without an 
infant schedule, and trials without clear reporting of numbers of enrolled infants and events in different periods of 
follow-up. For all reported periods of follow-up, we extracted the mean duration of follow-up (time since administration 
of the final dose of rotavirus vaccination), the number of enrolled infants, and case counts for rotavirus-positive 
severe gastroenteritis in both non-vaccinated and vaccinated groups. We used a Bayesian hierarchical Poisson meta-
regression model to estimate the pooled cumulative vaccine efficacy (VE) and its waning with time for three mortality 
strata. We then converted these VE estimates into instantaneous VE (iVE).
Findings In settings with low mortality (15 observations), iVE pooled for infant schedules of Rotarix and RotaTeq was 
98% (95% credibility interval 93–100) 2 weeks following the final dose of vaccination and 94% (87–98) after 12 months. 
In medium-mortality settings (11 observations), equivalent estimates were 82% (74–92) after 2 weeks and 77% (67–84) 
after 12 months. In settings with high mortality (24 observations), there were five different vaccines with observation 
points for infant schedules. The pooled iVE was 66% (48–81) after 2 weeks of follow-up and 44% (27–59) after 
12 months.
Interpretation Rotavirus vaccine efficacy is lower and wanes more rapidly in high-mortality settings than in 
low-mortality settings, but the earlier peak age of disease in high-mortality settings means that live oral rotavirus 
vaccines are still likely to provide substantial benefit.
Funding Bill & Melinda Gates Foundation.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Rotavirus gastroenteritis is estimated to cause around 
200 000 child deaths each year,1–3 mostly in sub-Saharan 
Africa and south Asia. Episodes of rotavirus gastroenteritis 
occur frequently in young children irrespective of living 
standards and are a major contributor to health-care costs 
worldwide.4,5
More than half of the countries in the world have 
introduced rotavirus vaccines into their national 
immunisation programmes.6 Infants typically receive two 
oral doses of Rotarix (GlaxoSmithKline Biologicals, 
London, UK) or three oral doses of RotaTeq (Merck & Co, 
Kenilworth, NJ, USA) in the first 6 months of life.7,8 Both 
vaccines have shown high and durable efficacy against 
episodes of severe rotavirus gastroenteritis in high-income 
settings but lower and less durable efficacy in sub-Saharan 
Africa and south Asia.9–12 Other live oral rotavirus vaccines 
are becoming available, such as ROTAVAC (Bharat 
Biotech, Hyderabad, India), ROTASIIL (Serum Institute 
of India, Pune, India), and RV3-BB (Murdoch Children’s 
Research Institute, Melbourne, Australia), but these 
vaccines have also reported low or waning efficacy in high-
mortality settings (eg, India, Indonesia, and Niger) when 
used as part of a standard infant schedule.13–16 Alternative 
schedules are being considered as one way to improve 
efficacy in the second year of life. Alternatives might 
involve administering the first dose at birth15 or 
administering a booster dose at age 9–12 months.17
Countries considering the introduction of rotavirus 
vaccine, global bodies such as WHO, and donors funding 
vaccine introduction in resource-poor settings require 
accurate projections of the potential effect of vaccination. 
Such projections are also useful in surveillance after 
vaccine introduction, to ensure that the vaccine is 
performing as expected and to estimate the remaining 
burden of disease after the vaccine has been introduced. 
Mathematical models can predict the potential effect of 
rotavirus vaccines but require credible estimates of vaccine 
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efficacy by duration of follow-up in different settings. This 
information is also crucial to the evaluation of alternative 
vaccination schedules. A large body of evidence now exists 
from high-quality randomised controlled trials (RCTs) in 
different parts of the world, but these data have never been 
pooled and synthesised to obtain robust estimates of 
vaccine efficacy by duration of follow-up. Combining this 
evidence is not straightforward. There is substantial 
variation in trial settings, follow-up periods, sample sizes, 
case definitions, and statistical methods used to calculate 
CIs. In addition, the main outcome reported in RCTs is the 
cumulative vaccine efficacy (VE) over a period of many 
weeks, but if there is evidence of vaccine waning, then 
the cumulative efficacy over the entire follow-up period 
might be different to the actual instantaneous VE (iVE) at 
different times within that period of follow-up.
Our aim is to estimate the instantaneous efficacy of 
live oral rotavirus vaccines by duration of follow-up (time 
since administration of the final dose of rotavirus 
vaccination) and by mortality strata.
Methods
Search strategy and selection criteria
We ran a meta-regression, in which we included all 
individual RCTs that were identified in a Cochrane 
systematic review of studies published until April 8, 2018,18 
and cross-checked the list against the studies identified by 
a review by Lamberti and colleagues.19 AC obtained the 
list of RCTs from the authors of the Cochrane review, 
cross-checked the list against the studies identified by a 
review by Lamberti and colleagues, extracted relevant 
data, and contacted the lead investigators of the study 
where further clarification was needed. A full assessment 
of the risks of bias associated with each rotavirus vaccine 
efficacy trial is described in detail in the Cochrane review.18 
We excluded trials that were based on special populations, 
trials without an infant schedule, and trials without clear 
reporting of enrolled infants and events in different 
periods of follow-up. The outcome measure was efficacy 
against episodes of severe rotavirus gastroenteritis, which 
is the primary endpoint reported in nearly all RCTs of 
rotavirus vaccines. Severe rotavirus gastroenteritis is 
defined as 11–20 points on the Vesikari scale,20 or for 
some older trials, 15–24 points on the Clark scale.21 If this 
outcome was not reported, we used the closest available 
proxy, such as efficacy against episodes of rotavirus 
gastroenteritis, which involved admission to hospital or 
the emergency department. In all studies, rotavirus-
positive episodes were detected by enzyme immunoassay. 
This study was approved by the ethics committee 
(Ref 15829) of the London School of Hygiene and Tropical 
Medicine.
Follow-up definition
We extracted vaccine efficacy for all reported periods of 
follow-up. Most of the studies reported results at two 
follow-up points. However, we also included studies with 
a single follow-up point. We extracted the number of 
individuals eligible for per-protocol analysis and the 
number of rotavirus-positive cases in both the non-
vaccinated and vaccinated groups. We also extracted the 
mean duration of follow-up in months. We extracted per-
protocol estimates because they exclude any disease cases 
reported in the first 14 days after vaccination and include 
only infants who received all recommended doses. We 
added 14 days to the reported mean duration of follow-up 
to calculate the entire period between administration of 
the last dose and the mean age at follow-up. If all infants 
in a study were followed up to a specific age (eg, 12 months), 
we subtracted the mean age of administration of the final 
dose (or target age if the mean was not reported) from the 
specific follow-up age.
Stratification of studies
To account for heterogeneity between the RCT sites, we 
grouped all 201 countries in the world into quintiles 
Research in context
Evidence before the study
In a Cochrane systematic review published in 2012, 
Soares-Weiser and colleagues identified 11 randomised 
controlled trials that showed that live oral rotavirus vaccines 
induce high and durable efficacy against episodes of severe 
rotavirus gastroenteritis in high-income settings, but lower 
and less durable efficacy in sub-Saharan Africa and south Asia.
Added value of this study
To our knowledge, this is the first study in which all the 
available evidence from randomised controlled trials has been 
synthesised to obtain robust estimates of efficacy by duration 
of follow-up. We include several new data points from Asia 
and use a novel approach to convert cumulative vaccine efficacy 
into instantaneous vaccine efficacy. Our analysis provides the 
most comprehensive evidence to date that rotavirus vaccine 
efficacy is lower and wanes more rapidly in high-mortality 
settings than in low-mortality settings. We show that, in 
Indonesia, a neonatal schedule provides more durable 
protection than the standard infant schedule, although this 
analysis was based on very few case counts in each week of 
follow-up.
Implications of all the available evidence
Live oral rotavirus vaccines are likely to provide substantial 
benefit globally. In high-mortality settings, strategies to 
optimise the effect of rotavirus vaccination warrant serious 
consideration. Estimates of the instantaneous efficacy of live 
oral rotavirus vaccines by duration of follow-up will be crucial 
to understanding the potential effect of alternative rotavirus 
vaccination schedules in different countries.
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(very low mortality, low mortality, medium mortality, 
high mortality, and very high mortality) using the 
under-5 mortality rate reported for the period 2010–15 in 
the 2017 revision of the UN Population Division database.22 
We further collapsed the very low and low quintiles and 
the high and very high quintiles to give three strata 
for deaths under age 5 years per 1000 livebirths: 
low (<13·5 deaths per 1000 livebirths), medium 
(13·5–28·1 deaths per 1000 livebirths), and high 
(>28·1 deaths per 1000 livebirths). Each RCT was then 
assigned to a specific stratum. For RCTs with multiple 
sites across several countries, we included each individual 
country as a separate observation point when this was 
possible. If RCT results were not disaggregated by country, 
we used the sample size in each site to calculate a weighted 
under-5 mortality rate and used this estimate to assign the 
trial to a specific mortality stratum. We restricted the 
pooled analysis to infant schedules only.
Recalculating cumulative vaccine efficacy for reported 
periods of follow-up
We observed substantial variation in the way authors 
estimated VE and 95% confidence intervals. Our pooled 
analyses used case counts and sample sizes reported in 
trials to generate credible intervals, but to ensure 
consistent reporting of the data in the summary table 
and plots, we also recalculated VE and 95% confidence 
intervals using the method of Daly and Altman.23,24 
VE was calculated as 1 – relative risk (RR) with 
zero inflation to 0·5.25
Efficacy by duration of follow-up and mortality strata
We used a Bayesian hierarchical meta-regression model 
to estimate cumulative VE by duration of follow-up. We 
generated separate pooled estimates for RCTs in low 
mortality, medium mortality, and high mortality strata. 
We assumed that errors around the observed numbers of 
cases in the unvaccinated and vaccinated groups followed 
Poisson distributions. The total number of cases in the 
unvaccinated group in study i and period p, termed Yi,p,u, 
was estimated  using the following generalised linear 
model:
Similarly, the total number of cases in the vaccinated 
group in study i and period p, termed Yi,p,v, was estimated 
using:
in which λi,p is the baseline rate of becoming infected, 
Pi,p,v and Pi,p,u are the total person-months of follow-up in 
the vaccinated and unvaccinated group, respectively, and 
θi(ti,p) is the cumulative relative risk (RR) in study i, at 
t months of follow-up. We used the log of the person-
time to estimate the log of the number of cases, so that 
the person-time was used on its identity scale when 
converting the cases to the identity scale. Total person-
months of follow-up was calculated as the number of 
participants at the beginning of the follow-up period 
multiplied by the reported mean duration of follow-up. 
The hierarchical component of the model ensured that 
parameter values of the study-specific RR were identical 
across periods in studies with more than one data point 
(eg, RR for period one and RR for period one plus two 
combined).
We estimated best-fitting model parameters using 
Markov Chain Monte Carlo methods. Gibbs sampling was 
used to draw from posterior distributions. We used non-
informative prior distributions for all parameters. We 
ran four parallel Markov Chain Monte Carlo chains and 
visually assessed whether chains converged. We report 
medians and 95% credible intervals from the posterior 
distributions of the cumulative VE. In the absence of any 
prior knowledge about the probable shape of waning, we 
explored several functional forms, including linear, power 
law, sigmoid, and gamma (appendix p 8). We assessed 
their goodness of fit using the deviance information 
criterion (DIC), visual assessment, and biological 
plausibility.
The best-fitting function of VE by duration of follow-up 
was used to estimate the iVE by duration of follow-up 
using a novel approach based on Kaplan-Meier survival 
estimates. More details about the method, including a 
derivation of the method, are provided in the appendix 
(p 1). The iVE at time t, termed 1 – σ(t), is retrieved using 
the following formula:
In this formula, iVE as a function of VE at time t is 
termed 1 – σ(t), all iVEs up until time t are termed 1 – σ(x), 
the baseline rate or force of infection at time t is termed 
λ(t), and all baseline rates up until time t are termed λ(x). 
ϑ denotes the relative rate, but we can only estimate 
relative risks (θ) with our dataset. Severe rotavirus 
gastroenteritis is a rare outcome, so we assume that θ is 
approximately equal to ϑ.
iVE and VE are identical at time t=0, that is to say 
1 – σ(0) = 1 – ϑ(0). The formula can then be used to iterate 
over all VEs to retrieve iVEs. If changes in baseline rates 
are not known, they can be assumed to be similar over 
time, so that:
For each stratum, we reported iVE at standard follow-
up times. We calculated empirical p values and credible 
log(Yi,p,u) = λi,p + log (Pi,p,u)
1 – σ(t) = 1 – (ϑ(t) – σ(x)) λ(x)
λ(t)
dxϑ(t) + ∫ t – 1
x = 0
log(Yi,p,v) = λi,p + log (Pi,p,v) + θi(ti,p)
See Online for appendix
λ(x)
λ(t)
= 1
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intervals to investigate differences between strata. We 
ran a sensitivity analysis to calculate iVE with and without 
observations from trials with large sample sizes.
Analyses were done using R version 3.4.326 and the 
rjags package.27 Code for the model and conversion 
method is provided online.28
Head-to-head comparison of efficacy for alternative 
schedules
To compare the efficacy and waning associated with 
different rotavirus vaccine schedules, we identified RCTs 
that directly compared different vaccine schedules head 
to head and requested more detailed unpublished 
information from the investigators on the number of 
case counts and individuals occurring in each week of 
follow-up after the last dose was administered. In sites 
with available data, we fitted the same models as in the 
pooled analysis but without the hierarchical parameters. 
These models used the same waning functions as in the 
pooled analysis (appendix, p 6) but with refitted 
parameters. Again, VE by duration of follow-up was 
converted to iVE, and we calculated empirical p values 
and credible intervals to investigate differences between 
schedules.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing 
of this report. The corresponding author had full access 
to all the data in the study and had final responsibility 
for the decision to submit for publication.
Results
We included 50 observation points from 50 observations 
published before April 4, 2018, in populations with low 
under-5 mortality (15 observations), medium under-5 
mortality (11 observations), and high under-5 mortality 
(24 observations) (table 1). We excluded trials that 
evaluated special groups, such as populations with high 
HIV prevalence46 and breastfed infants.47 We excluded 
the Finnish Extension Trial48,49 because the results could 
not be disentangled from a pooled estimate for five 
European countries reported separately.42 For the 
pooled analysis we focused on infant schedules, so 
Schedule Vaccine brand Score* Mean follow-up 
(months since 
final dose) 
Non-vaccinated group† Vaccinated group Cumulative efficacy 
(95% confidence 
intervals) 
Mean age 
(weeks) 
at dose 1
Doses Cases Number of 
individuals
Cases Number of 
individuals
High-mortality countries
Bangladesh9 10·0 2 Rotarix V11–20 8·1 35 301 9 292 73% (45 to 87)
Malawi10 11·0 2 Rotarix V11–20 7·7 38 483 21 525 49% (15 to 70)
Malawi10 11·0 2 Rotarix V11–20 15·6 53 483 38 525 34% (2 to 56)
South Africa‡11 11·0 2 Rotarix V11–20 7·7 9 408 5 418 46% (–60 to 82)
South Africa‡11 11·0 2 Rotarix V11–20 15·6 13 408 9 418 32% (–56 to 71)
Malawi10 6·2 3 Rotarix V11–20 7·7 38 483 20 505 50% (15 to 70)
Malawi10 6·2 3 Rotarix V11–20 15·6 53 483 32 505 42% (12 to 62)
South Africa‡11 6·2 3 Rotarix V11–20 7·7 9 408 1 425 89% (16 to 99)
South Africa‡11 6·2 3 Rotarix V11–20 15·6 13 408 2 425 85% (35 to 97)
Bangladesh12 8·3 3 RotaTeq V11–20 8·0 31 565 17 563 45% (2 to 69)
Bangladesh12 8·3 3 RotaTeq V11–20 14·7 56 565 33 563 41% (11 to 61)
Ghana29 8·4 3 RotaTeq V11–20 8·0 42 1081 15 1081 64% (36 to 80)
Ghana29 8·4 3 RotaTeq V11–20 14·5 57 1081 26 1081 54% (28 to 71)
Kenya29 7·3 3 RotaTeq V11–20 8·1 12 611 2 610 83% (26 to 96)
Kenya29 7·3 3 RotaTeq V11–20 12·3 14 611 5 610 64% (1 to 87)
Mali§29 6·9 3 RotaTeq V11–20 8·5 4 921 4 921 0% (–299 to 75)
Mali29 6·9 3 RotaTeq V11–20 14·9 58 921 48 921 17% (–20 to 43)
Niger14 6·8 3 ROTASIIL V11–20 5·6 87 1728 31 1780 65% (48 to 77)
India¶13 6·9 3 ROTASIIL V11–20 8·3 94 3498 61 3527 36% (11 to 53)
India13 6·9 3 ROTASIIL V11–20 20·0 275 3502 171 3533 38% (26 o 49)
India16 6·8 3 ROTAVAC V11–20 8·2 64 2187 56 4354 56% (37 to 69)
India16 6·8 3 ROTAVAC V11–20 13·4 76 2187 71 4354 53% (35 to 66)
Indonesia||15 9·3 3 RV3-BB V11–20 7·5 17 504 4 511 77% (32 to 92)
Indonesia||15 9·3 3 RV3-BB V11–20 13·5 28 504 14 511 51% (7 to 74)
(Table 1 continues on next page)
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excluded the neonatal RotaShield trial50 in Ghana and 
the neonatal schedule group of the RV3-BB trial15 in 
Indonesia. The neonatal schedule group of the 
RV3-BB trial15 was included in a separate head-to-head 
comparison of the infant and neonatal schedule in 
Indonesia.
Most of the data points (41 [82%] of 50) were reported 
using a Vesikari score of 11–20. There were 24 data points 
for Rotarix, 19 for RotaTeq, two for RV-3BB, three for 
ROTASIIL, and two for ROTAVAC. More data points 
(30 [60%] of 50) were based on a three-dose schedule 
than a two-dose schedule (20 [40%] of 50). The mean age 
of administration for the first dose ranged from 
6 weeks to 13 weeks.
We estimated VE and iVE (median and 95% credible 
intervals) by duration of follow-up (figure 1, table 2). In 
settings with low mortality (15 observations), iVE pooled for 
infant schedules of Rotarix and RotaTeq was 98% 
(95% credibility interval 93–100) 2 weeks following the final 
dose of vaccination and 94% (87–98) after 12 months. 
Equivalent pooled estimates for medium-mortality settings 
(11 observations) were 82% (74–92) after 2 weeks and 
77% (67–84) after 12 months. In settings with high mortality 
(24 observations), there were five vaccines with observation 
points for infant schedules. The pooled iVE was 66% (48–81) 
after 2 weeks of follow-up and 44% (27–59) after 12 months.
We found good evidence that iVE was significantly lower 
in medium-mortality settings than in low-mortality 
Schedule Vaccine brand Score* Mean follow-up 
(months since 
final dose) 
Non-vaccinated group† Vaccinated group Cumulative efficacy 
(95% confidence 
intervals)
Mean age
(weeks) 
at dose 1
Doses Cases Number of 
individuals
Cases Number of 
individuals
(Continued from previous page)
Medium-mortality countries
China30 9·6 2 Rotarix V11–20 4·0 32 1573 8 1575 75% (46 to 88)
China30 9·6 2 Rotarix V11–20 16·5 75 1573 21 1575 72% (55 to 83)
Latin America31 (n=3) 8·4 2 Rotarix V11–20 7·5 34 454 27 1392 74% (58 to 84)
Latin America32 (n=6) 8·6 2 Rotarix V11–20 7·9 19 2099 7 4211 82% (56 to 92)
Latin America33 (n=10) 8·0 2 Rotarix V11–20 8·8 58 7081 10 7205 83% (67 to 91)
Latin America33 (n=10) 8·0 2 Rotarix V11–20 20·5 161 7081 32 7205 80% (71 to 87)
China34 8·5 3 RotaTeq V11–20 9·8 52 1946 11 1930 79% (59 to 89)
Latin America35 (n=5) 9·7 3 RotaTeq Hosp/ED 19·0 10 2237 1 2252 90% (22 to 99)
USA36 (Navajo) >6 3 RotaTeq C11–24 8·8 37 403 4 392 89% (69 to 96)
Vietnam12 9·7 3 RotaTeq V11–20 8·0 7 442 2 446 72% (–36 to 94)
Vietnam12 9·7 3 RotaTeq V11–20 12·3 15 442 5 446 67% (10 to 88)
Low-mortality countries
Europe37 (n=6) 11·5 2 Rotarix V11–20 5·3 60 1302 5 2572 96% (90 to 98)
Europe37 (n=6) 11·5 2 Rotarix V11–20 17·3 127 1302 24 2572 90% (85 to 94)
Finland38 8·3 2 Rotarix V11–20 5·3 5 123 1 245 90% (15 to 99)
Finland38 8·3 2 Rotarix V11–20 17·3 10 123 3 245 85% (46 to 96)
Japan39 7·7 2 Rotarix V11–20 20·6 12 250 2 498 92% (63 to 98)
Southeast Asia40 (n=3) 12·0 2 Rotarix V11–20 7·4 15 5256 0 5263 97% (46 to 100)
Southeast Asia40 (n=3) 12·0 2 Rotarix V11–20 31·7 64 5256 2 5263 97% (87 to 99)
Southeast Asia40 (n=3) 12·0 2 Rotarix V11–20 19·5 51 5256 2 5263 96% (84 to 99)
USA41 13·0 2 Rotarix All RVGE 7·0 18 107 2 108 89% (54 to 97)
Europe42 (n=5) 10·0 3 RotaTeq C17–24 13·3 43 1188 0 1120 99% (80 to 100)
Europe42 (n=5)¶ 10·0 3 RotaTeq C17–24 19·0 61 1155 1 1088 98% (87 to 100)
USA35 9·7 3 RotaTeq Hosp/ED 19·0 58 12 179 3 12 284 95% (84 to 98)
Finland and USA43 10·0 3 RotaTeq C17–24 4·4 6 661 0 651 92% (–38 to 100)
Japan44 7·6 3 RotaTeq C17–24 6·7 10 381 0 380 95% (19 to 100)
USA45 >8 3 RotaTeq C17–24 5·5 8 183 0 187 94% (1 to 100)
The cumulative efficacy for reported periods of follow-up after two or three doses of live oral rotavirus vaccines are shown. *Scores denote the points on the Vesikari scale 11–20 (V11–20) or Clark scale 17–24 
(C17–24). All RVGE denotes any severity of rotavirus-positive gastroenteritis. Hosp/ED denotes rotavirus-positive hospitalisation or emergency department visit.†All randomised controlled trials were placebo 
controlled with the exception of the Rotarix trial in Bangladesh. ‡Data only extracted for the South African cohort that was followed for two successive seasons. §There were surveillance issues in the first year of 
trial in Mali that have been postulated to contribute to the low efficacy in the first period, but we did not adjust for this. ¶N values were adjusted to be the same for both follow-up periods in the Bayesian 
meta-regression. ||For the neonatal schedule, the cumulative efficacy was 94% (95% CI 55–99) after about 9 months of follow-up and 75% (43–89) after about 15 months.
Table 1: Observations from published randomised controlled trials included in the pooled analysis of infant schedules
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settings after 2 weeks and 12 months of follow-up. The 
median absolute percentage point difference in iVE was 
16% (95% credibility interval 4–24, p=0·0023) at 2 weeks 
and 17% (8–28, p=0·0022) at 12 months. We found weak 
evidence that iVE was significantly lower in high-mortality 
settings compared with medium-mortality settings after 
2 weeks and strong evidence that iVE was lower after 
12 months. The median difference was 16% (95% credibility 
interval –1 to 38, p=0·089) at 2 weeks and 33% (15 to 51, 
p=0·0011) at 12 months.
Two large studies in India (of ROTAVAC16 and 
ROTASIIL)13 were included in the high-mortality stratum. 
Given their large sample sizes, we investigated whether 
these two studies were driving the results in the high-
mortality setting. Therefore, we ran a sensitivity analysis 
to calculate iVE with and without the Indian data points, 
and for India alone (table 2; appendix p 27). We found no 
evidence that iVE significantly differed after 2 weeks or 
12 months of follow-up when excluding the Indian data 
points from the high-mortality stratum. The median 
difference absolute percentage point difference in iVE 
was –13% (95% credibility interval –39 to 16, p=0·81) 
after 2 weeks and 8% (–22 to 42, p=0·31) after 12 months.
A simple power function was fitted in all strata because 
Figure 1: Median and 95% credible intervals of cumulative and instantaneous vaccine efficacy by duration of follow-up and setting after two or three doses 
of oral rotavirus vaccination (infant schedules only)
A simple power function was used to represent vaccine waning over time; equivalent plots based on other potential waning functions are available in the appendix 
(p 10). Each blue dot represents the VE for each observation. The size of the dot represents the relative sample size of the study. The error bars represent 95% CIs 
around the VE. VE=vaccine efficacy. 
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Time since final dose of vaccination (weeks) Time since final dose of vaccination (weeks)
Low mortality
Low-mortality 
countries
Medium-mortality 
countries
High-mortality 
countries
High-mortality 
countries (except India)
India
2 weeks 98% (93 to 100) 82% (74 to 92) 66% (48–81) 81% (56–94) 54% (–78 to 88)
1 month 98% (93 to 100) 81% (74 to 90) 62% (47–75) 74% (53–88) 52% (–89 to 88)
2 months 97% (93 to 99) 80% (73 to 87) 57% (45–67) 66% (50–79) 49% (–105 to 87)
3 months 96% (92 to 99) 79% (73 to 86) 54% (44–64) 61% (48–72) 48% (–108 to 86)
6 months 95% (91 to 98) 78% (71 to 84) 49% (40–61) 49% (38–64) 45% (–115 to 86)
9 months 95% (89 to 98) 77% (69 to 84) 46% (33–60) 42% (22–61) 43% (–124 to 86)
12 months 94% (87 to 98) 77% (67 to 84) 44% (27–59) 36% (5–60) 42% (–128 to 85)
18 months 94% (83 to 97) 77% (63 to 84) 41% (17–58) 27% (–26 to 59) 41% (–135 to 85)
24 months 93% (79 to 97) 76% (59 to 83) 38% (9–58) 19% (–54 to 57) 40% (–139 to 85)
36 months 92% (69 to 97) 76% (53 to 83) 35% (–4 to 57) 7% (–107 to 56) 39% (–149 to 85)
48 months 91% (58 to 97) 75% (48 to 83) 32% (–14 to 57) –2% (–154 to 56) 38% (–154 to 85)
60 months 91% (48 to 97) 75% (44 to 83) 30% (–23 to 57) –10% (–200 to 55) 37% (–163 to 85)
Table 2: Median instantaneous vaccine efficacy and 95% credible intervals by duration of follow-up and setting after two or three doses of oral rotavirus 
vaccination (infant schedules only)
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this required the fewest assumptions and parameters 
and had goodness of fit (DIC scores) that were 
consistently favourable across all strata of interest 
compared with other functions (appendix p 8). Results 
for alternative functions are shown in the appendix 
(p 10).
We found few RCTs with head-to-head comparisons of 
different schedules. In Indonesia, a three-dose neonatal 
RV3-BB schedule (administered at 0–5 days, 8–10 weeks, 
and 14–16 weeks) was compared with a three-dose RV3-BB 
infant schedule (administered at 8–10 weeks, 14–16 weeks, 
and 18–20 weeks).15 For the neonatal schedule, the VE was 
94% (95% confidence interval 55–99) after about 9 months 
of follow-up and 75% (43–89) after about 15 months. For 
the infant schedule, VE was 77% (32–92) after about 
8 months and 51% (7–74) after about 14 months (table 1). 
For this trial, we were able to obtain the number of events 
in each week of follow-up to better inform estimates of 
iVE over time. For the neonatal schedule, the estimated 
iVE was 98% (92–100) after 2 weeks, 77% (73–80) after 
6 months, and 57% (42–69) after 12 months of follow-up. 
For the standard infant schedule, iVE was 95% (89–98) 
after 2 weeks, 60% (55–64) after 6 months, and 31% (12–48) 
after 12 months of follow-up (figure 2). We found no 
significant difference between the two schedules after 
2 weeks of follow-up, but strong evidence that the neonatal 
schedule had higher iVE after 6 months and 12 months of 
follow-up. The median difference in iVE was 3% (–1 to 10, 
p=0·088) after 2 weeks of follow-up, 17% (13 to 22, 
p=0·00049) after 6 months, and 26% (13 to 48, p=0·017) 
after 12 months.
We used a simple power function for the head-to-head 
analyses because it required the minimum number of 
assumptions and parameters and had favourable DIC 
scores (appendix p 8). Results for alternative functions 
are also shown in the appendix (p 19).
The only other trial with head-to-head comparison of 
schedules was a multicountry trial comparing infant 
schedules of Rotarix in South Africa and Malawi. We were 
unable to obtain the underlying dataset for this trial. In 
both countries, a three-dose schedule (administered at 
6 weeks, 10 weeks, and 14 weeks) had higher VE than the 
two-dose schedule (administered at 10 weeks and 
14 weeks), but the CIs were wide (table 1).
Discussion
Our analysis showed that live oral rotavirus vaccines 
provide high and durable protection in low-mortality and 
medium-mortality settings. Efficacy is lower and wanes 
more rapidly in high-mortality settings, but in these 
settings, more than 60% of rotavirus gastroenteritis 
hospital admissions occur before age 1 year, and more 
than 90% occur before age 2 years.51 Thus, live oral 
rotavirus vaccines are still likely to provide substantial 
benefit in these settings, irrespective of waning.
The reasons for lower rotavirus vaccine efficacy in 
resource-poor settings are not well understood. 
Immunogenicity studies have shown lower geometric 
mean concentrations in resource-poor settings than in 
high-income settings.52 Hypotheses for lower immuno- 
genicity include interference by maternal antibodies, 
interference by oral polio vaccines, neutralising factors 
present in breastmilk, malnutrition, other enteric 
coinfections, rotavirus strain diversity, and HIV infection. 
Competition in the gut has also been proposed as a reason 
for the lower performance of oral polio vaccine in 
resource-poor settings.53–55 Research is underway to assess 
the role of maternal antibodies and gut microbiota in the 
immune response to rotavirus vaccines in British, 
Malawian, and Indian infants.56 Two pivotal cohort studies 
from Mexico57 and India58 have reported contrasting 
estimates of the protection conferred by natural infections 
against subsequent disease. In Mexico (a medium-
mortality setting), two previous infections (asymptomatic 
Figure 2: Median and 95% credible intervals of cumulative and instantaneous vaccine efficacy by duration of follow-up and type of schedule (neonatal vs 
infant) following three doses of RV3-BB in Indonesia
A simple power function was used to represent vaccine waning over time; equivalent plots based on other potential waning functions are available in the appendix 
(p 19). Data points shown on the left-hand panel represent observed vaccine efficacies derived from cumulative Kaplan-Meier hazard ratios, and error bars with their 
corresponding 95% confidence intervals. Solid lines and dashed lines represent medians. Shaded areas represent 95% credible intervals.
•••
••••••••••••••••••••••••••••••••
•••••••••••••••
•••••••••••••••
Cumulative Instantaneous
0 50 100 150 0 50 100 150
−20
0
20
40
60
80
100
Va
cc
in
e 
effi
ca
cy
Time since final dose of vaccination (weeks) Time since final dose of vaccination (weeks)
Neonatal
Infant
Vaccine schedule
Articles
8 www.thelancet.com/infection   Published online June 6, 2019   http://dx.doi.org/10.1016/S1473-3099(19)30126-4
or symptomatic) conferred 100% protection against 
subsequent moderate or severe rotavirus gastroenteritis. 
In India (a high-mortality setting), the equivalent pro- 
tection was 57% after two previous infections (and 79% 
after three previous infections). If natural infections are 
less likely to protect against moderate and severe rotavirus 
gastroenteritis in higher-mortality settings than in lower-
mortality settings, then a live oral vaccine mimicking 
natural infection might also have lower estimated efficacy 
in children in these settings.
The reported declines in instantaneous efficacy might 
not be entirely caused by declining vaccine-induced 
antibodies. Some of the decrease could be explained by a 
higher incidence of natural asymptomatic and mild 
infections (and thus preferential immune boosting) 
among unvaccinated controls compared with vaccine 
recipients. In these circumstances the risk of severe 
rotavirus gastroenteritis in vaccine recipients would 
gradually converge with, and might exceed, the risk in 
unvaccinated controls over time. This phenomenon has 
been described previously in the context of so-called 
leaky vaccines.59 Our analysis of the infant and neonatal 
schedules for RV3-BB in Indonesia suggested a positive 
protective effect of the vaccine in the first 18 months of 
follow-up, but extrapolation of the curves suggested a 
negative effect thereafter. This would be consistent 
with preferential natural boosting among non-vaccine 
recipients but is speculative, because it involves extra- 
polating beyond the observed period of follow-up in the 
trial. Reanalysis of data from an RCT in Bangladesh60 has 
allowed these effects to be partly disentangled by 
excluding any children who had an episode of non-severe 
rotavirus gastroenteritis. This finding explained some, 
but not all, of the reduction in vaccine efficacy over time. 
However, it was not possible to exclude infants who had 
previous asymptomatic infections, which might also 
have an important role.
Head-to-head comparisons of schedules for the same 
vaccine were rare, and more evidence is needed from 
more places on the relative benefits of one schedule over 
another. In our analysis of RV3-BB in Indonesia, the 
neonatal schedule provided more durable protection 
than the infant schedule, but this analysis was based on 
few case counts in each week of follow-up. A neonatal 
schedule is also likely to result in higher and earlier 
coverage and fewer vaccine-related intussusception 
events than an infant schedule, so warrants serious 
consideration. Other strategies that could help to improve 
the effect of the vaccines include administering a booster 
dose later in infancy17,61 or using injectable non-replicating 
vaccines,62 but more evidence is needed on the safety and 
clinical efficacy of both of these options.
For the pooled analysis, we combined evidence for 
different vaccine products and different infant schedules 
to avoid having small numbers of data points in each 
stratum. None of the RCTs compared different brands 
of rotavirus vaccination head to head in the same 
population. There were several observations for RotaTeq 
and Rotarix, but the Rotarix sites included data points 
from South Africa, which had higher efficacy and lower 
child mortality relative to the sites evaluated in the 
RotaTeq trials. Thus, in the absence of head-to-head 
comparisons from the same trial populations, there is 
insufficient evidence to favour one product over another 
in terms of vaccine efficacy and duration of protection. 
However, the postlicensure experience of countries that 
have used both Rotarix and RotaTeq does not suggest any 
material difference in vaccine effect.63
Most of the data points were reported against the 
Vesikari 11–20 scale, but some were reported against the 
Clark 16–24 scale. These two scores correlate poorly with 
one another when estimating the proportion of rotavirus 
gastroenteritis episodes defined as severe.64,65 However, 
this bias is unlikely to change the conclusion that 
protection is high and durable in the low-mortality 
stratum, in which the Clark scale was more commonly 
used.
We stratified our results by mortality and presented 
pooled results with and without data points from 
potentially influential studies. We restricted the analysis 
to RCTs because they represent the gold standard 
approach for measuring per-protocol vaccine efficacy and 
provide accurate information about the mean duration of 
follow-up. Other designs, such as case-control studies, do 
not permit precise estimation of the mean duration of 
follow-up. Some case-control studies report vaccine 
effectiveness by age band, and thus could potentially be 
used to derive the duration of follow-up, but this 
approach becomes increasingly crude as the width of the 
age band increases. Case-control studies are also at risk 
of bias because infants who have been vaccinated might 
be different from those who are unvaccinated for both 
known and unknown reasons. We also restricted the 
analysis to per protocol rather than by intention to treat 
because this analysis provided a consistent basis for 
pooling the different RCTs, ensuring that all infants 
received the recommended number of doses and that a 
more consistent starting point was used for the 
measurement of follow-up. Accurate estimates of iVE 
following a single dose of rotavirus vaccination would be 
useful for informing the potential effects of different 
schedules, but typically there are few infants who receive 
only a single dose, and even fewer of those infants are 
followed up for the full duration of the trial.
We reported the initial peak efficacy starting at 2 weeks 
of follow-up because of uncertainty around the time that 
antibodies might take to develop after vaccination. In 
addition, we had to extrapolate our fitted estimates of VE 
to periods without empirical data (eg, beyond 2 years of 
follow-up). The absence of empirical data from RCTs is 
represented by larger credible intervals in these periods. 
However, this makes comparison of different waning 
functions difficult. Evidence from RCTs with a longer 
duration of follow-up or high-quality observational 
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studies is needed to overcome this knowledge gap. A 
so-called no-waning model required only one parameter, 
and for this reason had favourable DIC scores in each of 
the pooled analyses. However, in Indonesia, where all 
data points were from the same trial, the DIC score was 
unfavourable. We considered no waning (or no change in 
RR) to be implausible, given that VE was shown to 
decrease in nearly all RCTs with more than one follow-up 
point. However, more studies with multiple follow-up 
times would be needed to have greater certainty about 
the appropriate form of vaccine waning.
We used a novel approach to convert estimates from 
cumulative VE to iVE. We show that this method is able 
to retrieve iVE, and that standard estimates of 
cumulative VE might overestimate iVE in the presence 
of waning. However, there are some limitations in 
applying this method to the meta-regression used in 
this study. First, it would be better to use relative rates 
than RR. We had to compute relative risks because most 
of the RCTs only reported observed numbers of cases 
and individuals at a limited number of follow-up times. 
However, because severe rotavirus gastroenteritis is a 
relatively rare outcome, risk ratios and rate ratios are 
expected to be similar, and we assume that this bias is 
negligible in our study. Second, waning of vaccine 
efficacy (or conversely, waxing of the relative rate) might 
interact with changes in baseline rates. This effect 
would be relatively small on the estimated VE, but 
might be pronounced when converted to an iVE. 
Because we had no information on changes in the 
baseline rates in our studies, we assumed that this rate 
was constant over time (an assumption that is often 
made in survival analyses) and did not correct for it. The 
bias is likely to be in the direction of increasing VE 
because baseline rates decline with age, particularly in 
high-mortality settings. Our method should ideally be 
extended to control for different changing baseline rates 
in different studies, as would be the case in a pooled 
analysis. However, even uncorrected iVE should still be 
a better approximation to true iVE than cumulative VE 
in the presence of waning.
Because the two Indian studies had larger sample sizes 
than other studies in the high-mortality stratum, we 
did a sensitivity analysis to see whether these studies 
significantly influenced our results. Exclusion of these 
studies did not alter our findings significantly. Moreover, 
an analysis in which we estimated iVE for India alone did 
not provide meaningful results, because there were only 
four observations, which is too few to generate a reliable 
pooled estimate in our analysis.
Reviews of the efficacy, effectiveness, and effects of 
rotavirus vaccines19,66,67 have described variation in 
rotavirus vaccine effects according to under-5 mortality 
and geographical region. However, to our knowledge, 
our study is the first to synthesise all the available 
RCT evidence and to obtain robust estimates of iVE by 
duration of follow-up. Our study should provide 
important evidence for estimating and monitoring the 
effects of rotavirus vaccines in different settings. Our 
analysis provides the most comprehensive evidence to 
date that rotavirus vaccine efficacy is lower and wanes 
more rapidly in high-mortality settings than in low-
mortality settings. The earlier peak age of disease in 
these settings means that live oral rotavirus vaccines are 
still likely to provide substantial benefit, but strategies 
with the potential to further increase the effects of 
vaccines, such as neonatal vaccination, warrant 
serious consideration. Monitoring the age distribution of 
rotavirus disease cases in the years following vaccine 
introduction will also be important. Consistent with the 
basic theory of infectious disease dynamics, a reduction 
in the incidence of infection (eg, from vaccination) 
should lead to an increase in the mean age of infection. 
As more children become infected at older ages, the need 
for more durable rotavirus vaccines might become more 
pressing.
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